A wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind’s new AI model can predict the structure of…
Good afternoon! The use of a buzzy class of weight loss and diabetes medications is more common than ever.survey
Medicare can only cover treatments for weight loss if they are approved in the U.S. for an additional health benefit, such as treating diabetes and reducing the risk of heart disease. The data points in this survey could change in the future as GLP-1s win approval for new purposes, such as sleep apnea and fatty liver disease, which would put more pressure on health plans to cover them. Stay tuned for our coverage on the use of these drugs.
The model was developed by Google DeepMind, which researches and builds AI systems, and Isomorphic Labs, which explores applications of AI within drug development. Since AlphaFold 3 includes a broad group of biomolecules, it goes beyond the capabilities ofDeepMind announced AlphaFold 2 in 2020. The model has since been used by"millions" of researchers to develop cancer treatments, malaria vaccines and design enzymes, Google said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Healthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey saysA wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind’s new AI model can predict the structure of…
Read more »
GLP-1s Could Benefit OSA, But Healthy Habits Are Still Key, Experts SayOSA management may be helpful in OSA but raises concerns about access to GLP-1s and abandoning lifestyle changes.
Read more »
One in 8 adults has used Ozempic or similar GLP-1 drugsOnly 12% of adults have tried GLP-1 drugs such as Ozempic to treat chronic disease or weight loss. It's even lower among Medicare patients.
Read more »
Healthy Returns: U.S. drug shortages reach record high, hitting Wegovy, ADHD medicationsU.S. medication shortages are at a record high so far this year. Meanwhile, UnitedHealth revealed the financial impact of the Change Healthcare cyberattack.
Read more »
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successorsAbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group’s CEO will testify on Capitol Hill.
Read more »
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successorsAbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group’s CEO will testify on Capitol Hill.
Read more »